Register for our free email digests:
Division of Merck & Co. Inc.
Latest From MSD India
Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.
More than two dozen brands, a sharp spurt in sales volumes and a price decline of over 60% currently appear to characterize the market for the type 2 diabetes therapy teneligliptin in India. And market watchers claim that teneligliptin volumes in the country have surpassed the combined numbers of some of the more established gliptins, including vildagliptin and sitagliptin.
A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon amid what some industry watchers say are early signs of a shake-up in volumes in the highly competitive domestic gliptins market.
Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export two of its diabetes therapies, or hope to introduce copies of these on the domestic market, infringing on its patents.
- Therapeutic Areas
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
KG Ananthakrishnan, Managing Dir.
Giri Giridhar, Sr. Dir., Fin.
Swashraya Shah, MD, Sr. Dir., Med. Affairs
Neelima Dwivedi, Sr. Dir., Corp. Affairs
- Contact Info
Phone: 22 67898888
Platina 8th Fl. C. 59, G Block
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.